Orexigen Therapeutics (OREX) 7.39 $OREX Today's Dead Cat

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 9:57 PM

Orexigen Therapeutics (OREX) 7.39 $OREX

Today's Dead Cat Bounce Stock: Orexigen Therapeutics (OREX)
at The Street - Wed Apr 22, 3:12PM CDT
Trade-Ideas LLC identified Orexigen Therapeutics (OREX) as a "dead cat bounce" (down big yesterday but up big today) candidate
OREX: 7.39 (+0.22)

Orexigen Faces Generic Challenge For Anti-Obesity Drug
Spencer Osborne - at Seeking Alpha - Wed Apr 22, 11:24AM CDT

OREX: 7.39 (+0.22), ACT: 295.22 (+0.69), VVUS: 2.50 (+0.04)

Novo's obesity drug will cost U.S. patients over $1,000 per month
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 9:52AM CDT

OREX: 7.39 (+0.22), NVO: 56.37 (-0.17), VVUS: 2.50 (+0.04), ARNA: 4.47 (+0.01)

Orexigen Announces Receipt of Paragraph IV Certification Notice
PR Newswire - Wed Apr 22, 6:30AM CDT
Orexigen Therapeutics, Inc. (NASDAQ: OREX) today announced that Orexigen and North American partner Takeda Pharmaceuticals have received notification of a Paragraph IV certification for certain patents for Contrave® (naltrexone HCl and bupropion HCl extended release) which are listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. The certification resulted from the filing by Actavis Laboratories FL, Inc. of an Abbreviated New Drug Application (ANDA) challenging such patents for Contrave.
OREX: 7.39 (+0.22)

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Orexigen Therapeutics, Inc. and a Lead Plaintiff Deadline of May 11, 2015
Business Wire - Tue Apr 21, 9:39AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Orexigen Therapeutics, Inc. ("Orexigen" or the "Company"

(NASDAQ:OREX) securities between March 3, 2015 and March 5, 2015.
OREX: 7.39 (+0.22)

3 Promising Small-Caps Under $10 You Can Buy Right Now
Dan Caplinger, Selena Maranjian, and Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 21, 8:06AM CDT
The healthcare arena is a hotbed of interesting small-cap plays, including Orexigen Therapeutics, the maker of the obesity drug Contrave. Image: Orexigen Therapeutics. Many investors are afraid of investing in small-cap stocks, believing that the...
MBI: 9.34 (+0.04), OREX: 7.39 (+0.22), ARNA: 4.47 (+0.01)

Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Orexigen Therapeutics, Inc.
Business Wire - Mon Apr 20, 9:54AM CDT
Glancy Binkow & Goldberg LLP reminds investors in Orexigen Therapeutics, Inc. ("Orexigen" or the "Company"

(NASDAQ: OREX) who purchased the Company's securities between March 3 and March 5, 2015, inclusive (the "Class Period"

of the May 11, 2015 deadline to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
OREX: 7.39 (+0.22)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Orexigen Therapeutics, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of May 11, 2015 - OREX
PR Newswire - Wed Apr 15, 9:17AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
OREX: 7.39 (+0.22)

Don't Write Off Arena As Yet
Emerging Equities - at Seeking Alpha - Wed Apr 15, 7:33AM CDT

OREX: 7.39 (+0.22), PFE: 34.93 (+0.04), ARNA: 4.47 (+0.01)

3 Promising Healthcare Stocks Under $10
Keith Speights, The Motley Fool - Motley Fool - Wed Apr 15, 7:02AM CDT
Source: Wikipedia.org Stocks can be cheap and expensive at the same time. Novice investors might mistakenly think that a stock with a low share price is a bargain. However, some of these stocks are actually overpriced because their future...
OREX: 7.39 (+0.22), PACB: 5.90 (-0.07), VVUS: 2.50 (+0.04), ILMN: 190.04 (-9.27), ABBV: 64.52 (+0.91), ARNA: 4.47 (+0.01), OSUR: 6.75 (-0.03)

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Orexigen Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Tue Apr 14, 4:02PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf of purchasers of Orexigen Therapeutics, Inc. ("Orexigen" or the "Company"

(Nasdaq: OREX) securities during the period between March 3, 2015 and March 5, 2015, inclusive (the "Class Period"

. Investors who wish to become proactively involved in the litigation have until May 11, 2015 to seek appointment as lead plaintiff.
OREX: 7.39 (+0.22)

Vivus Sales Remain Flat - Stock Trend Not Good
Spencer Osborne - at Seeking Alpha - Mon Apr 13, 12:19PM CDT

OREX: 7.39 (+0.22), VVUS: 2.50 (+0.04), ARNA: 4.47 (+0.01)

Arena's 15,000 Scripts Set Pace Vs. Competitors
Spencer Osborne - at Seeking Alpha - Mon Apr 13, 10:00AM CDT

OREX: 7.39 (+0.22), ARNA: 4.47 (+0.01)

Law Offices of Howard G. Smith Reminds Investors of Orexigen Therapeutics, Inc. of the May 11, 2015 Deadline
Business Wire - Mon Apr 13, 9:30AM CDT
Law Offices of Howard G. Smith reminds investors who purchased Orexigen Therapeutics, Inc. ("Orexigen" or the "Company"

(NASDAQ:OREX) between March 3, 2015 and March 5, 2015, inclusive (the "Class Period"

of the May 11, 2015 lead plaintiff deadline. Investors are advised to contact the law firm to discuss their legal rights concerning the class action pending before the District Court for the Southern District of California.
OREX: 7.39 (+0.22)

Orexigen: Contrave Scripts Dip - Were My Concerns About Advertising Right?
Spencer Osborne - at Seeking Alpha - Mon Apr 13, 9:23AM CDT

OREX: 7.39 (+0.22), VVUS: 2.50 (+0.04), ARNA: 4.47 (+0.01)

The Best Stock to Invest in Obesity Drugs
Brian Orelli, The Motley Fool - Motley Fool - Sun Apr 12, 1:03PM CDT
Considering the limited number of obesity drugs, it seems easiest to pick the best stock in the field by process of elimination. Company Drug FDA Approved? Roche Xenical Yes VIVUS ...
ZFGN: 39.06 (+0.36), OREX: 7.39 (+0.22), NVO: 56.37 (-0.17), VVUS: 2.50 (+0.04), ARNA: 4.47 (+0.01)

OREXIGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Orexigen Therapeutics, Inc.
Business Wire - Fri Apr 10, 9:00PM CDT
Kahn Swick & Foti, LLC ("KSF"

and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 11, 2015 to file lead plaintiff applications in a securities class action lawsuit against Orexigen Therapeutics, Inc. (Nasdaq: OREX) if they purchased the Company's securities between March 3, 2015 and March 5, 2015, inclusive (the "Class Period"

. This action is pending in the United States District Court for the Southern District of California.
OREX: 7.39 (+0.22)

Orexigen Therapeutics to Speak at the Needham Healthcare Conference
PR Newswire - Fri Apr 10, 3:01PM CDT
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a corporate overview at the 2015 Needham Healthcare Conference in New York. The presentation is scheduled for Tuesday, April 14th at 12:50 p.m. Eastern Time. To listen to the live webcast or a replay of the discussion, please visit the Investors section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
OREX: 7.39 (+0.22)

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Orexigen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - OREX
PR Newswire - Fri Apr 10, 12:45PM CDT
Pomerantz LLP has filed a class action lawsuit against Orexigen Therapeutics, Inc. ("Orexigen" or the "Company"

(NASDAQ: OREX) and certain of its officers. The class action, filed in United States District Court, Southern District of California, is on behalf of a class consisting of all persons or entities who purchased Orexigen securities between March 3, 2015 and March 5, 2015, inclusive (the "Class Period"

. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act"

.
OREX: 7.39 (+0.22)

Arena's Partner Eisai Is Slashing Jobs - What Investors Need To Consider
Spencer Osborne - at Seeking Alpha - Fri Apr 10, 9:27AM CDT

OREX: 7.39 (+0.22), ARNA: 4.47 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Endurance Energy's Modular Tech Revs Up Southeast Asia

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

Jackson Wang's Fantasy IP Hits Hong Kong Stage

A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...

Quay Sunglasses: Luxury Looks, Affordable Prices

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

AST SpaceMobile Faces Class Action Over Misstatements

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

HONA Faces Legal Heat: Investor Lawsuit Over Losses

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Farm Aid 2026: A Resilient Tribute to Family Farmers

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

PACS Group Faces Legal Scrutiny: What to Watch

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...

Geron Corp Faces Fiduciary Duty Investigation

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

China Southern Airlines Marks 70th Anniversary in NYC

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Timur Turlov Leads FIDE with Chess and Digital Focus

An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...